Our Work
Latham & Watkins Advises Cheplapharm on Private Placement
October 21, 2026
Latham represents European leader in well-established medicines in its issuance of senior secured notes totaling €390 million.
Latham & Watkins LLP has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a European leader in well-established medicines, on a private placement of €390 million senior secured notes.
The refinancing follows Cheplapharm’s recently announced €1.2 billion term loan B financing as well as the announcement of Cheplapharm’s strategic partnership with Sanofi. Latham & Watkins advised Cheplapharm on both of these transactions.
The Latham team was led by Munich Capital Markets partner Rüdiger Malaun and Frankfurt Capital Markets partner Jan Penselin, with associates Peter Neuböck and Tobias Müller. Advice was also provided on tax matters by Munich partner Ulf Kieker.